rejuvant life tabs

Bridging the gap between Longevity science and clinicians

Latest articles

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

New research institute focuses on science of aging

New Bakar Aging Research Institute aims to drive deeply collaborative research to enhance translational medicine, progressing novel therapies from lab to clinic to community. UC...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...
Rejuvant

Deep Longevity continues to build its life-extension ecosystem with a new structured course on Longevity medicine.

Deep Longevity, the Insilico spin-out which was acquired by Regent Pacific, has announced it is launching a First Introduction to Longevity Medicine for Physicians course on LabXchange Platform. The course seeks to provide a comprehensive Longevity medicine curriculum for clinicians, covering topics of bioregontology, geroscience and AI-based medicine.

Longevity.Technology: Aging is the greatest risk factor for most acute and chronic diseases, and although we are on the cusp of being able to intervene in the aging process to effectively decrease overall mortality and morbidity rates for an aging population, Longevity research is far ahead of medicine progress-wise. Deep Longevity’s new course aims to bridge this gap, bringing clinicians up to speed with recent advances in aging and Longevity interventions and bringing anti-aging out of the lab and into the clinic.

Deep Longevity has considerable experience in explainable AI systems and aging clocks that track aging rates on multiple levels. The new course which aims to fill the educational gap in translation longevity medicine will leverage this, covering a broad foundation of translational aging research terminology, theories and hallmarks of aging, basic aging pathways and mechanisms behind geroprotective interventions.

“As we are partnering with the advanced clinical institutions we see the gap between translational research and clinical practice and would like to provide the MDs with the resources they need to get into the rapidly growing field of longevity medicine, learn about the latest advances in artificial intelligence and in the pharmaceutical industry,” said Alex Zhavoronkov, PhD, the founder of the Longevity Medicine course and Chief Longevity Officer at Deep Longevity.

COVIDomic is an open access tool to stratify risk and severity from multimodal data sets ,including multi-omics data.
Alex Zhavoronkov, PhD, the founder of the Longevity Medicine course

Longevity Medicine for Physicians contains three hours of core lectures, as well as lecture slides and notes, quizzes, guest lectures and references to additional reading materials and online resources. It is intended to be the first course in a series that will aim to provide advanced physicians with the latest approaches in Longevity technology.

“While much-scattered information is available from more or less evidence-based sources, there was a lack of a structured, guided and well organised course that provides physicians with the necessary background information on this rapidly evolving discipline of healthy longevity. This is why we developed this very first course in Longevity Medicine – to close this gap and provide understandable and practicable, credible resources for clinicians,” said Evelyne Bischof, MD, co-founder of the course.

Elevant

Evelyne Bischof, MD, co-founder of the course

Speaking to Longevity.Technology, Dr Bischof was enthusiastic about the new course.

“Longevity medicine will become the medicine of the future,” she told us. “And physicians are missing the train because we have so much other stuff to learn every single day. But if we don’t jump on the train right now to educate ourselves about it, then it will be too late. Having a course that is validated, credible, certified and approved by medical societies and bodies will hopefully help to change that.”

Our interview with Dr Evelyne Bischof will be published tomorrow – stay tuned!

Images courtesy of BoxerX / Shutterstock, Dr Bischof and Deep Longevity

1 COMMENT

Comments are closed.

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

New investor offers funding to healthy aging innovators

A fifth investor has joined UK Research and Innovation (UKRI), providing matched funding for top small innovators to develop ideas for healthy aging. The new...

Connected care start-up targets aging-in-place

PCL Health monitors key vitals at home, providing caregivers with peace of mind and supporting aging-in-place. British start-up PCL Health (formerly Poonyah Care) is on...

AgeTech fund: focus on over-50s not millennials

Founding partner of 1843 Capital targets AgeTech investment opportunities with $13 million fund. Connecticut-based early stage investment firm 1843 Capital values diversity highly, and seeks...

Gut bacteria start-up exits stealth with unique data

Wild Biotech plans to use database of more than 1,200 gut microbes to pursue novel drugs for human diseases and enhance CRISPR editing. Wild Biotech,...

AI first: novel drug target and novel molecule discovered

One step closer to senescence moonshot: Insilico claims industry first by nominating preclinical candidate for IPF, with both novel drug target and novel molecule...
Supps report ad middle